PG&E has suffered one of the utility sector's sharpest single-month drops. The stock is down 26.8% in September alone. Now Wall Street is formally catching up — and the options market is reading the selloff as overdone.
UBS is the latest to turn cautious. Analyst Gregg Orrill downgraded PG&E to Neutral this morning, slashing his price target 26% from $19 to $14. The stock trades at $12.88 — already below that new target.
The downgrade caps a brutal three-week stretch for sell-side coverage. Truist Securities also downgraded to Hold on September 3, cutting its target from $21 to $17. B of A Securities downgraded to Neutral on September 1, dropping its target from $24 to $13. Morgan Stanley kept its Equal-Weight rating but trimmed its target from $22 to $20 on September 18.
The consensus has shifted to Hold, with 9 Hold ratings against 6 Buys. The mean price target stands at $19.22 — still 49% above the current price, which illustrates how disorderly the selloff has been relative to where analysts have anchored their models.
Despite the analyst gloom, options positioning tells a contrarian story. The put-call ratio hit 0.1775 on September 22 — 2.35 standard deviations above its 20-day mean. That sounds alarming, but the PCR is extremely low in absolute terms. At 0.1775, calls still vastly outnumber puts. The z-score simply reflects how far the ratio has moved from its own subdued baseline. The 52-week high PCR was 0.6656 — still low by any cross-sector standard. Options traders are not expressing fear. They are buying calls into weakness.
The borrow market offers no squeeze thesis here. Availability sits at 4,226% — more than 2 billion shares available to borrow against a relatively small short position. That is a vast pool of supply. Short interest stands at 1.9% of free float, up 25% over the past month in share terms, but still a low absolute level. The cost to borrow ticked up 64.5% intraweek to a brief peak before retreating to 0.33% — cheap by any standard. Shorts face no structural pressure from the lending market.
Earnings are due October 22. That is the next hard catalyst. The analyst consensus is converging around the $13–$14 range — but at $12.88, the stock already trades through those targets. How management frames California's regulatory environment on that call will determine whether the sell-side can find a floor.
See the live data behind this article on ORTEX.
Open PCG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
